Market Cap
CA$58.8m
Last Updated
2020/06/06 03:42 UTC
Data Sources
Company Financials +
Executive Summary
Sernova Corp., a clinical-stage regenerative medicine therapeutics company, focuses on the development and commercializing of its proprietary Cell Pouch System and associated technologies, including the cell pouch and systemic and/or locally immune protected therapeutic cells and tissues.
Risk Analysis
Currently unprofitable and not forecast to become profitable over the next 3 years
+ 1 more risk
Snowflake Analysis
Adequate balance sheet with weak fundamentals.
Share Price & News
How has Sernova's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: SVA's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
53.8%
SVA
0.2%
CA Biotechs
4.1%
CA Market
1 Year Return
39.5%
SVA
41.6%
CA Biotechs
-8.6%
CA Market
Return vs Industry: SVA underperformed the Canadian Biotechs industry which returned 41.6% over the past year.
Return vs Market: SVA exceeded the Canadian Market which returned -8.6% over the past year.
Shareholder returns
| SVA | Industry | Market | |
|---|---|---|---|
| 7 Day | 53.8% | 0.2% | 4.1% |
| 30 Day | 100.0% | 4.8% | 7.9% |
| 90 Day | 87.5% | -5.5% | -3.4% |
| 1 Year | 39.5%39.5% | 41.6%41.6% | -5.5%-8.6% |
| 3 Year | 33.3%33.3% | 51.8%51.8% | 3.6%-6.1% |
| 5 Year | 36.4%36.4% | -34.2%-34.2% | 21.4%3.5% |
Price Volatility Vs. Market
How volatile is Sernova's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall St
Does Sernova Corp. (CVE:SVA) Have A Volatile Share Price?2 months ago | Simply Wall St
We're Keeping An Eye On Sernova's (CVE:SVA) Cash Burn Rate10 months ago | Simply Wall St
Those Who Purchased Sernova (CVE:SVA) Shares Three Years Ago Have A 28% Loss To Show For ItValuation
Is Sernova undervalued compared to its fair value and its price relative to the market?
15.7x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate SVA's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate SVA's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: SVA is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: SVA is unprofitable, so we can't compare its PE Ratio to the Canadian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate SVA's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: SVA is overvalued based on its PB Ratio (15.7x) compared to the CA Biotechs industry average (4.9x).
Next Steps
Future Growth
How is Sernova forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
79.4%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SVA is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: SVA is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: SVA is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: Insufficient data to determine if SVA's revenue is forecast to grow faster than the Canadian market.
High Growth Revenue: Insufficient data to determine if SVA's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if SVA's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has Sernova performed over the past 5 years?
-8.8%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: SVA is currently unprofitable.
Growing Profit Margin: SVA is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: SVA is unprofitable, and losses have increased over the past 5 years at a rate of -8.8% per year.
Accelerating Growth: Unable to compare SVA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SVA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.5%).
Return on Equity
High ROE: SVA has a negative Return on Equity (-123.1%), as it is currently unprofitable.
Next Steps
Financial Health
How is Sernova's financial position?
Financial Position Analysis
Short Term Liabilities: SVA's short term assets (CA$3.9M) exceed its short term liabilities (CA$472.0K).
Long Term Liabilities: SVA has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: SVA is debt free.
Reducing Debt: SVA has not had any debt for past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: SVA has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: SVA has less than a year of cash runway if free cash flow continues to reduce at historical rates of 17.4% each year
Next Steps
Dividend
What is Sernova's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate SVA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate SVA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if SVA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if SVA's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of SVA's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
11.0yrs
Average board tenure
CEO
Philip Toleikis
11.17yrs
Tenure
CA$793,214
Compensation
Dr. Philip M. Toleikis, B.A., M.Sc., Ph.D., has been the Chief Executive Officer and the President of Sernova Corp. since April 28, 2009. Dr. Toleikis is a seasoned and Experienced biotechnology executive, ...
CEO Compensation Analysis
Compensation vs Market: Philip's total compensation ($USD591.68K) is above average for companies of similar size in the Canadian market ($USD163.24K).
Compensation vs Earnings: Philip's compensation has increased whilst the company is unprofitable.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 11.17yrs | CA$793.21k | 2.65% CA$1.6m | |
| Independent Director | 8.17yrs | CA$74.62k | 0.11% CA$64.4k | |
| Independent Chairman | 5.25yrs | CA$102.41k | 0.13% CA$75.0k | |
| Member of Scientific Advisory Board | 13.92yrs | no data | no data | |
| Independent Director | 11.67yrs | CA$77.12k | 0.29% CA$168.5k | |
| Member of Scientific Advisory Board | 13.83yrs | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | 13.5yrs | no data | no data | |
| Member of Scientific Advisory Board | 9.5yrs | no data | no data | |
| Independent Director | 1.17yrs | CA$27.06k | no data |
11.0yrs
Average Tenure
54yo
Average Age
Experienced Board: SVA's board of directors are seasoned and experienced ( 11 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 13.8%.
Top Shareholders
Company Information
Sernova Corp.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Sernova Corp.
- Ticker: SVA
- Exchange: TSXV
- Founded:
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: CA$58.784m
- Shares outstanding: 195.95m
- Website: https://www.sernova.com
Location
- Sernova Corp.
- The Stiller Centre
- 700 Collip Circle
- London
- Ontario
- N6G 4X8
- Canada
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| SVA | TSXV (TSX Venture Exchange) | Yes | Common Shares | CA | CAD | Feb 2000 |
| SEOV.F | OTCPK (Pink Sheets LLC) | Yes | Common Shares | US | USD | Feb 2000 |
| PSH | DB (Deutsche Boerse AG) | Yes | Common Shares | DE | EUR | Feb 2000 |
Biography
Sernova Corp., a clinical-stage regenerative medicine therapeutics company, focuses on the development and commercializing of its proprietary Cell Pouch System and associated technologies, including the cell pouch and systemic and/or locally immune protected therapeutic cells and tissues. Its Cell Pouch system is a medical device designed to create a vascularized tissue environment for the transplantation and engraftment of therapeutic cells or tissues for the treatment of diabetes, hemophilia, hypothyroid disease, and other severe chronic diseases. The company has a research collaboration with AgeX Therapeutics, Inc. to generate immune-protected universal therapeutic cells. Sernova Corp. is headquartered in London, Canada.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/06/06 03:42 |
| End of Day Share Price | 2020/06/05 00:00 |
| Earnings | 2020/01/31 |
| Annual Earnings | 2019/10/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.